Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial.
- DOI
- 10.1007/s10549-026-08091-4
- Published
- 2026 Nov 9
- Container
- Breast cancer research and treatment
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s10549-026-08091-4,
title = {Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial.},
author = {Zhang M and Qin Y and Wan J and Tian Z and Zhang Z and Zhu X and Fan D and Yang L and Hou L and Zhang H and Zhao G and Wang T and Zhang J},
year = {2026},
journal = {Breast cancer research and treatment},
doi = {10.1007/s10549-026-08091-4},
url = {https://doi.org/10.1007/s10549-026-08091-4}
}RIS
TY - JOUR TI - Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial. AU - Zhang M AU - Qin Y AU - Wan J AU - Tian Z AU - Zhang Z AU - Zhu X AU - Fan D AU - Yang L AU - Hou L AU - Zhang H AU - Zhao G AU - Wang T AU - Zhang J PY - 2026 JO - Breast cancer research and treatment DO - 10.1007/s10549-026-08091-4 UR - https://doi.org/10.1007/s10549-026-08091-4 ER -
APA
M, Z., Y, Q., J, W., Z, T., Z, Z., X, Z., D, F., L, Y., L, H., H, Z., G, Z., T, W., & J, Z. (2026). Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial.. Breast cancer research and treatment. https://doi.org/10.1007/s10549-026-08091-4
Source records
- pubmed · retrieved 2026-11-10T16:51:15.256Z